HOME >> MEDICINE >> NEWS
Aspirin withdrawal may pose risk to coronary patients

(Orlando, Florida, October 29, 2003) -- Patients with coronary artery disease who stop taking aspirin may be at risk for developing withdrawal-related coronary events, says a new study presented at CHEST 2003, the 69th annual international scientific assembly of the American College of Chest Physicians (ACCP). The study found that previously stable coronary patients experienced coronary events, including unstable angina and myocardial infarction (heart attack), within one week of aspirin withdrawal.

"The benefits of aspirin therapy in coronary patients are well known. However, the effects that aspirin withdrawal has on this group of patients are just now being studied," said lead author Emile Ferrari, MD, Professor of Cardiology, University Hospital Pasteur, Nice, France. "Our study shows that aspirin therapy can not be safely stopped in any case, but especially in patients with a history of coronary disease."

Researchers from University Hospital Pasteur reviewed the cases of 1,236 patients hospitalized for coronary syndromes to determine which patients were hospitalized due to treatment withdrawal. Of those hospitalized, 51patients experienced acute coronary events, including unstable angina, stent thrombosis, and heart attacks, less than one week after aspirin withdrawal. Prior to hospitalization, patients had been taking aspirin for at least three months. Although patients had a history of heart attacks and stable angina, none had an unstable coronary event prior to aspirin withdrawal. Reasons for aspirin withdrawal included minor surgery, dental treatment, and non-compliance. Aspirin therapy is standard in patients with coronary artery disease because of its ability to thin the blood and reduce the risk of developing acute blockage in the coronary arteries.

"Coronary patients preparing for dental work or surgery are often advised to stop taking aspirin in order to avoid increased bleeding," said Dr. Ferrari. "Our study serves as
'"/>

Contact: Arielle Green
agreen@chestnet.org
847-498-8387
American College of Chest Physicians
29-Oct-2003


Page: 1 2

Related medicine news :

1. Aspirins potential ability to prevent colon polyps may not apply equally to all
2. Aspirin underused to reduce heart disease risk in diabetic women and young adults
3. Long Island Breast Cancer Study data: Aspirin helps protect some women against breast cancer
4. Aspirin use associated with reduced risk of breast cancer
5. Aspirin use may be associated with increased risk of pancreatic cancer
6. Aspirin is most cost effective way to prevent heart disease
7. Aspirin does not reduce effectiveness of ACE inhibitors
8. Aspirin may help prevent pancreatic cancer
9. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus
10. Aspirin within two days of ischemic stroke reduces deaths
11. Aspirin steps up as anti-inflammatory for arteries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aspirin withdrawal may pose risk coronary patients

(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, ... acquire a second language, new research suggests. But anyone who ... a brain boost, the small study finds. The ... co-author Ping Li, co-director of the Center for Brain, Behavior ... interesting, Li said, that "the brain networks of the more ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 In ... an inventor from Sharpes, Fla., designed an easy way to ... lowering it/them. , He then created a prototype of the ... lift or lower a toilet seat and/or lid in a ... which prevents the spread of germs. Overall, it promotes good ...
(Date:11/27/2014)... New York, New York (PRWEB) November 27, 2014 ... behalf of individuals who were allegedly injured by the ... court, where a federal litigation is looking ahead to ... , According to a Scheduling Order issued earlier ... take place on December 16th at 10:00 a.m. Items ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 “LAB.C” was featured ... features the latest and coolest technology products available to consumers. ... the product review and shared with viewers the ... iOS and Android devices. , Consumers love portability and functionality. ... Their Cable Case for the iPhone5 and 5S has a ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
(Date:11/27/2014)... Ireland , November 27, 2014 ... Investigational New Drug (IND) Application with the U.S. Food ... in Hovione,s strategy of developing improved drug delivery options ... for minocycline gel, a novel formulation using a new ... one of the most widely prescribed oral antibiotics for ...
(Date:11/26/2014)... Company plc ("Perrigo") (NYSE: PRGO ; TASE), ... today announced the closing of Perrigo,s previously announced registered ... shares at a public offering price of $152.00 per ... purchase up to an additional 888,157 ordinary shares by ... representatives of the several underwriters. Perrigo ...
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
Breaking Medicine Technology:Hovione Files its First Investigational New Drug Application With the FDA 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
Cached News: